Stock SLNCF SILENCE THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

News Silence Therapeutics plc OTC Markets

Equities

SLNCF

GB00B9GTXM62

Delayed OTC Markets
Other stock markets
 12:20:48 2024-04-18 EDT 		5-day change 1st Jan Change
8 USD -.--% Intraday chart for Silence Therapeutics plc -.--% +433.33%
04-29 Silence Therapeutics plc Announces Retirement of Alistair Gray from Board of Directors, Effective May 1, 2024 CI
04-19 European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
BU
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
BU
Silence Therapeutics plc Announces Retirement of Alistair Gray from Board of Directors, Effective May 1, 2024
CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down
MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading
MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
MT
Silence Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION - Form 6-K
PU
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading
MT
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
BU
Silence Therapeutics plc Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
CI
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading
MT
European Equities Traded in the US as American Depositary Receipts Start Week Slightly Lower in Monday Trading
MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Friday Trading
MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading
MT
Chardan Boosts Price Target on Silence Therapeutics to $42 From $26 on Positive Data From Zerlasiran Study, Keeps Buy Rating
MT
Morgan Stanley Boosts Price Target on Silence Therapeutics to $45 From $29, Says Q4 Showed 'Meaningful Progress,' Keeps Overweight Rating
MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading
MT
Silence Therapeutics Says Phase 2 Study of High Lipoprotein(a) Treatment Meets Primary Endpoint
MT
Sector Update: Health Care Stocks Gain Premarket Wednesday
MT
Transcript : Silence Therapeutics plc, Q4 2023 Earnings Call, Mar 13, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SLN Stock
  4. SLNCF Stock
  5. News Silence Therapeutics plc
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW